2024
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.
Nader Marta G, Chu X, Mukhopadhyay S, Abramson V, Brufsky A, Stringer-Reasor E, Dent S, Traina T, Carey L, Rimawi M, Specht J, Miller K, Santa-Maria C, Dasgupta T, Binboğa Kurt B, Tayob N, Krop I, Tung N, Schnitt S, Mayer E. Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030. Journal Of Clinical Oncology 2024, 42: 555-555. DOI: 10.1200/jco.2024.42.16_suppl.555.Peer-Reviewed Original ResearchTriple negative breast cancerTumor-infiltrating lymphocytesArea under the curveEvaluation of tumor-infiltrating lymphocytesCore needle biopsyNeoadjuvant chemotherapyPredictive of responseOdds ratioReceiver operating characteristicImmune microenvironmentEarly-stage triple negative breast cancerPre-treatment core needle biopsyPrediction of response to NACBaseline tumor-infiltrating lymphocytesEvaluate tumor-infiltrating lymphocytesStromal tumor-infiltrating lymphocytesResponse to NACTumor-infiltrating lymphocyte scoresResponse to neoadjuvant chemotherapyImmune responseCombined immune responseNegative breast cancerH&E-stained slidesCell cycle aberrationsCell cycle signature
2023
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley K, Parker J, Singh B, Campbell J, Ballman K, Hillman D, Winer E, El-Abed S, Piccart M, Di Cosimo S, Symmans W, Krop I, Salgado R, Loi S, Pusztai L, Perou C, Carey L, Sotiriou C. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications 2023, 14: 7053. PMID: 37923752, PMCID: PMC10624889, DOI: 10.1038/s41467-023-42635-2.Peer-Reviewed Original ResearchConceptsEvent-free survivalHER2-positive breast cancerPathological complete responseCALGB 40601Breast cancerBreast pathological complete responseStromal tumor-infiltrating lymphocytesHormone receptor statusPhase III trialsClinical nodal statusIndependent prognostic factorTumor-infiltrating lymphocytesIdentification of patientsBreast cancer prognosisT cell receptorNeoadjuvant paclitaxelNeoadjuvant therapyIII trialsNodal statusComplete responsePrognostic factorsPrognostic scoreReceptor statusClinicopathological featuresResidual disease
2019
The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
Waks AG, Stover DG, Guerriero JL, Dillon D, Barry WT, Gjini E, Hartl C, Lo W, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, Yang F, Sullivan A, Danaher P, Brauer HA, Osmani W, Lipschitz M, Hoadley KA, Goldberg M, Perou CM, Rodig S, Winer EP, Krop IE, Mittendorf EA, Tolaney SM. The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy. Clinical Cancer Research 2019, 25: 4644-4655. PMID: 31061067, PMCID: PMC6677598, DOI: 10.1158/1078-0432.ccr-19-0173.Peer-Reviewed Original ResearchConceptsStromal tumor-infiltrating lymphocytesImmune microenvironmentNeoadjuvant chemotherapyPD-L1Breast cancerHormone receptor-positive breast cancerBreast tumorsHormone receptor-positive/HER2-negative breast cancerHER2-negative breast cancerDistant metastasis-free survivalReceptor-positive breast cancerImmunotherapy-based approachesPAM50 intrinsic subtypesCheckpoint inhibitor therapyPD-L1 stainingTumor-infiltrating lymphocytesMetastasis-free survivalMacrophage-targeted therapiesRole of macrophagesPreoperative chemotherapyStandard chemotherapyInhibitor therapyResidual diseaseMyeloid signaturePoor response